The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Development of a novel chimeric oncolytic viral platform, CF33 and its derivatives, for peritoneal-directed CF33-OV treatment of gastric cancer peritoneal carcinomatosis.
 
Annie Yang
No Relationships to Disclose
 
Zhifang Zhang
No Relationships to Disclose
 
Shyambabu Chaurasiya
No Relationships to Disclose
 
Anthony K Park
Consulting or Advisory Role - Imugene
Research Funding - Imugene
Patents, Royalties, Other Intellectual Property - Oncolytic virus licensed to Imugene Limited
Travel, Accommodations, Expenses - Imugene
 
Audrey Jung
No Relationships to Disclose
 
Jianming Lu
No Relationships to Disclose
 
Sang-In Kim
No Relationships to Disclose
 
Saul Priceman
Stock and Other Ownership Interests - Adicet Bio; Imugene
Consulting or Advisory Role - Adicet Bio; Bayer; Imugene; MustangBio
Research Funding - Carisma Therapeutics; Imugene
Patents, Royalties, Other Intellectual Property - CAR Therapeutic; Oncolytic Virus Therapeutic
 
Yuman Fong
Stock and Other Ownership Interests - Imugene; Pfizer (I)
Consulting or Advisory Role - Imugene; Johnson & Johnson; Medtronic; Perfint Healthcare; Sangamo Bioscience; Vergent Bioscience
Patents, Royalties, Other Intellectual Property - Viral Vector licensed to Imugene; Viral vector licensed to Merck
 
Yanghee Woo
Consulting or Advisory Role - Imugene; Johnson and Johnson (Ethicon)
Travel, Accommodations, Expenses - Imugene